Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Azelastine - Meda

Drug Profile

Azelastine - Meda

Alternative Names: Afluon; Allergodil; Astelin; Astepro; Astepro Extra Strength; Astepro Once-Daily; Azelastine extra strength; Azelastine HCl; Azelastine hydrochloride; Azelastine nasal spray; MP03-33; MP03-36; Optilast; Optivar; Rhinolast

Latest Information Update: 24 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Muro Pharmaceutical
  • Developer Meda
  • Class Antiallergics; Azepines; Chlorinated hydrocarbons; Ketones; Phthalazines; Small molecules
  • Mechanism of Action Histamine H1 receptor antagonists; Mast cell stabilisers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Allergic conjunctivitis; Allergic rhinitis; Perennial allergic rhinitis; Rhinitis; Seasonal allergic rhinitis

Most Recent Events

  • 05 Aug 2016 Meda has been acquired by Mylan
  • 12 May 2014 Generic equivalent of Astepro® (intranasal) approved in USA for Allergic rhinitis
  • 20 Mar 2012 The EMA approves azelastine (improved formulation; Astepro®) for Allergic rhinitis in European Union
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top